The Goldman Sachs Group Cuts GoodRx (NASDAQ:GDRX) Price Target to $2.50

GoodRx (NASDAQ:GDRX) had its price target reduced by The Goldman Sachs Group from $4.00 to $2.50 in a research report report published on Monday morning,Benzinga reports. They currently have a neutral rating on the stock.

Several other equities analysts have also weighed in on the company. Weiss Ratings reissued a “sell (d)” rating on shares of GoodRx in a report on Tuesday, December 23rd. Barclays began coverage on GoodRx in a research note on Monday, December 8th. They set an “underweight” rating and a $3.00 price target for the company. UBS Group lowered their price objective on GoodRx from $4.25 to $4.00 and set a “neutral” rating on the stock in a research note on Thursday, November 6th. TD Cowen dropped their price objective on shares of GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Finally, Morgan Stanley reduced their target price on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Thursday, December 18th. Five research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $3.98.

GoodRx Price Performance

GDRX opened at $2.18 on Monday. GoodRx has a fifty-two week low of $1.77 and a fifty-two week high of $5.81. The firm has a 50-day moving average of $2.47 and a 200 day moving average of $3.23. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.61 and a current ratio of 2.61. The firm has a market cap of $739.96 million, a P/E ratio of 24.22, a PEG ratio of 1.43 and a beta of 1.52.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09. GoodRx had a net margin of 3.82% and a return on equity of 9.31%. The business had revenue of $194.79 million for the quarter, compared to analyst estimates of $193.27 million. During the same quarter in the previous year, the firm posted $0.09 earnings per share. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, research analysts expect that GoodRx will post 0.13 EPS for the current year.

Institutional Trading of GoodRx

A number of hedge funds and other institutional investors have recently bought and sold shares of GDRX. Meridian Wealth Management LLC purchased a new stake in GoodRx in the 4th quarter worth approximately $29,000. Quarry LP purchased a new stake in shares of GoodRx in the third quarter worth $33,000. MML Investors Services LLC purchased a new stake in shares of GoodRx in the fourth quarter worth $36,000. DRW Securities LLC bought a new stake in GoodRx during the fourth quarter valued at $40,000. Finally, Boothbay Fund Management LLC purchased a new position in GoodRx during the third quarter worth about $43,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.